Filtered By:
Drug: Medroxyprogesterone
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 487 results found since Jan 2013.
Contraceptive exposure associates with urinary tract infection risk in a cohort of reproductive-age women: a case control study
CONCLUSION: This study notes potential for a small increase in UTIs with contraceptive use. Prospective studies are required before this information is applied in clinical settings.CONDENSATION: Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is poorly understood. This large-cohort, case-control study notes potential for a small increase in UTIs with contraceptive use.PMID:36537554 | DOI:10.1080/13625187.2022.2156278
Source: The European Journal of Contraception and Reproductive Health Care - December 20, 2022 Category: Reproduction Medicine Authors: Claire Lo Abin Abraham Cosmin A Bejan Seth A Reasoner Mario Davidson Loren Lipworth David M Aronoff Source Type: research
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study
Jpn J Clin Oncol. 2022 Dec 8:hyac184. doi: 10.1093/jjco/hyac184. Online ahead of print.NO ABSTRACTPMID:36484305 | DOI:10.1093/jjco/hyac184
Source: Clinical Breast Cancer - December 9, 2022 Category: Cancer & Oncology Authors: Hidetoshi Kawaguchi Yutaka Yamamoto Shigehira Saji Norikazu Masuda Takahiro Nakayama Kenjiro Aogi Keisei Anan Shoichiro Ohtani Nobuaki Sato Toshimi Takano Eriko Tokunaga Seigo Nakamura Yoshie Hasegawa Masaya Hattori Tomomi Fujisawa Satoshi Morita Miki Yam Source Type: research
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.PMID:36401943 | DOI:10.1016/j.ygyno.2022.10.018
Source: Gynecologic Oncology - November 19, 2022 Category: Cancer & Oncology Authors: Minh Tung Phung Penelope M Webb Anna DeFazio Sian Fereday Alice W Lee David D L Bowtell Peter A Fasching Ellen L Goode Marc T Goodman Beth Y Karlan Jenny Lester Keitaro Matsuo Francesmary Modugno James D Brenton Toon Van Gorp Paul D P Pharoah Joellen M Sc Source Type: research
